Abstract: The extensive adoption of cloud computing platforms in storing and processing data have brought forth a new age of efficiency in the way data is stored, processed and managed, requiring new ...

Abstract: Nowadays, as the demand for accurate object detection (OD) applications is increasing, several attempts have been made to introduce convolutional neural network (CNN)-based super-resolution ...

The following slide deck was published by Recursion Pharmaceuticals, Inc. in conjunction with this event.

Hi, everyone, and welcome. I'm Najat Khan, Recursion's Chief R&D and Chief Commercial Officer and incoming CEO and President. Let's jump right in. Today is an important moment for Recursion, for our ...

Additionally, Recursion shared promising results from its ongoing Phase 1b/2 TUPELO trial for the drug REC-4881, showing significant polyp reduction in patients with familial adenomatous polyposis.

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Investing.com -- Recursion Pharmaceuticals (NASDAQ:RXRX) stock rose 7% Monday following positive Phase 2 trial results for its experimental drug REC-4881 in familial adenomatous polyposis (FAP), a ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

For our new docs at work, we want to convert LaTeX to Markdown. The problem is that it has quite a lot of nested documents with \include, which Docsify can only go one level deep.

Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a ...